Leading health care economist and public policy expert John C. Goodman, PhD, breaks down what various supply chain entities can expect with TrumpRx.
John C. Goodman, PhD
Advertisement
John C. Goodman, PhD, senior fellow at the Independent Institute and president of the Goodman Institute for Public Policy Research
Articles by John C. Goodman, PhD
In part 3 of our interview with John C. Goodman, PhD, he discusses how TrumpRx could impact the drug supply chain—specifically PBMs.
John C. Goodman, PhD, discusses TrumpRx’s impact on patients and pharmacies, comparing this administration’s approach with the previous Biden Administration.
John C. Goodman, PhD, senior fellow at the Independent Institute, discusses TrumpRx and its goals for patients’ OOP drug costs.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Drug Topics
1
Congressional Spending Bill to Include Key PBM Contracting Reform
2
Meeting at the Crossroads: The Role and Impact of PBMs and BOPs on Pharmacists
3
Pharma, OTC Supplement Are Markets Expected to Grow Billions Come 2032
4
Q&A: New Medicare Drug Prices Proving Detrimental to Pharmacy Cashflow
5